A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients

Trial Profile

A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Ozanimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms RADIANCE
  • Sponsors Celgene Corporation; Receptos
  • Most Recent Events

    • 28 Oct 2017 Results assessing brain volume loss at 1 and 2 year from two phase III trials (SUNBEAM and RADIANCE) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Oct 2017 Results of analysis assessing cardiac safety of ozanimod in RADIANCE and QT/QTc trials (see CTP 239937) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results from part B of this trial and pre-specified pooled analysis of the RADIANCE and SUNBEAM trials presented in a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top